Titan Pharmaceuticals, Inc. (NASDAQ:TTNP – Get Free Report) shares crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $4.37 and traded as high as $4.39. Titan Pharmaceuticals shares last traded at $3.98, with a volume of 40,794 shares.
Analyst Ratings Changes
Separately, StockNews.com began coverage on Titan Pharmaceuticals in a report on Saturday. They set a “sell” rating on the stock.
Check Out Our Latest Analysis on TTNP
Titan Pharmaceuticals Trading Up 1.5 %
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last announced its quarterly earnings data on Friday, January 3rd. The specialty pharmaceutical company reported ($0.83) earnings per share for the quarter.
Titan Pharmaceuticals Company Profile
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
See Also
- Five stocks we like better than Titan Pharmaceuticals
- Bank Stocks – Best Bank Stocks to Invest In
- Autodesk Designs Value for Investors: Uptrend Set to Continue
- About the Markup Calculator
- Anheuser-Busch Stock Rallies—Is the King of Beers Back?
- What is the Hang Seng index?
- MarketBeat Week in Review – 02/24 – 02/28
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
